Earnings8-K
Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
ALT
Altimmune, Inc.
A clinical-stage biopharmaceutical company developing pemvidutide, a balanced GLP-1 and glucagon dual receptor agonist in late-stage trials for fatty-liver disease (MASH), alcohol use disorder, and alcohol-associated liver disease. It began in 1997 as vaccine maker Vaxin Inc. before renaming to Altimmune in 2015, and its early work included NasoVAX, a needle-free intranasal flu vaccine.
CUSIP: 02155H200HealthcareUS1 holder